Abstract Background HER2-positive (HER2+) breast cancer (BC) comprises all the four
PAM50 molecular subtypes. Among these, the HER2-Enriched (HER2-E) appear to be …

Pathologic complete response (pCR) following neoadjuvant therapy has been associated
with improved event-free survival (EFS) and overall survival (OS) in early-stage breast …

Purpose: Neoadjuvant immunotherapy may improve the clinical outcome of regionally
advanced operable melanoma and allows for rapid clinical and pathologic assessment of …

Neoadjuvant therapy is integral to the treatment of early-stage breast cancer. Goals of
treatment include surgical downstaging of the tumor, rendering inoperable tumors …

Purpose: In breast cancer, pathologic complete response (pCR) to neoadjuvant systemic
therapy (NST) is associated with favorable long-term outcome. Trastuzumab emtansine as …

Neoadjuvant therapy in breast cancer refers to systemic therapy administered prior to
definitive surgery. It was originally developed for patients with locally advanced breast …

In der Prävention und Behandlung des frühen Mammakarzinoms sind über die Jahre immer
wieder kleine, aber bedeutsame Fortschritte gemacht worden. In der Prävention gewinnen …

Systemic therapy for breast cancer may be given before (neoadjuvant) or after (adjuvant)
surgery. When neoadjuvant systemic therapy is given, response to treatment can be …

Health technology assessment (HTA) of clinical and economic value of a new intervention is
an integral step in providing the access of patients to innovative cancer care and treatment …

Background: This retrospective, observational study examined real-world treatment patterns
and effectiveness outcomes in 450 patients with stage II–IIIB early-stage triple-negative …